Related references
Note: Only part of the references are listed.Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Antonio Passaro et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation
Elham Nafea Alsahafi et al.
CANCER LETTERS (2021)
Extensive functional evaluation of exon 20 insertion mutations of EGFR
Takeshi Hirose et al.
LUNG CANCER (2021)
Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction
Myungjin Lee et al.
CELL DEATH & DISEASE (2021)
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
Zhenfang Du et al.
NATURE COMMUNICATIONS (2021)
Prolonged cetuximab treatment promotes p27Kip1-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma
Kohei Okuyama et al.
SCIENTIFIC REPORTS (2021)
Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
Sandra Ortiz-Cuaran et al.
FRONTIERS IN ONCOLOGY (2021)
An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy
Garrett Anderson et al.
CANCERS (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
Rui-Fang Dong et al.
PHARMACOLOGICAL RESEARCH (2021)
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
Tereza Vaclova et al.
NATURE COMMUNICATIONS (2021)
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne P. Robichaux et al.
NATURE (2021)
Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification
Guoqing Zhang et al.
ONCOLOGIST (2021)
Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis
Xishan Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer
Tasia Bos et al.
FRONTIERS IN ORAL HEALTH (2021)
EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas
Gyorgyi A. Nelhubel et al.
PATHOLOGY & ONCOLOGY RESEARCH (2021)
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy
Morena Fasano et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
Sindhu Nair et al.
PLOS ONE (2020)
The Role of Cancer Stem Cells in Radiation Resistance
Christoph Reinhold Arnold et al.
FRONTIERS IN ONCOLOGY (2020)
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis
Haijing Liu et al.
CANCER COMMUNICATIONS (2020)
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
Svenja Wagener-Ryczek et al.
BMC CANCER (2020)
Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer
Marsha-Kay N. D. Hutchinson et al.
ONCOGENE (2020)
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Head and neck squamous cell carcinoma
Daniel E. Johnson et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Jordi Remon et al.
CANCER TREATMENT REVIEWS (2020)
The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
Zhe Zhao et al.
JOURNAL OF CANCER (2020)
Investigational multitargeted kinase inhibitors in development for head and neck neoplasms
Ana Marija Sola et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
Alessandro Russo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope
Laura Orellana et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2019)
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Tianli Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer
Weiwei Hong et al.
ONCOLOGY LETTERS (2019)
Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
Pierre Coliat et al.
CANCERS (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Overview of current systemic management of EGFR-mutant NSCLC
W. -H. Hsu et al.
ANNALS OF ONCOLOGY (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lower gingival squamous cell carcinoma with brain metastasis during long-term cetuximab treatment: A case report
Tomofumi Naruse et al.
ONCOLOGY LETTERS (2018)
Mechanism of acquired resistance to cetuximab in head and neck cancer.
Arun Khattri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Friederike Braig et al.
CANCER RESEARCH (2017)
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
Nicola Normanno et al.
ONCOTARGET (2017)
Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression
Daniela Alterio et al.
MEDICAL ONCOLOGY (2017)
Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma
Chittibabu Vatte et al.
ONCOTARGETS AND THERAPY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells
Muzafar A. Macha et al.
ONCOTARGET (2017)
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The Rotation Model
Endang R. Purba et al.
CELLS (2017)
Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review
Christos Perisanidis
IN VIVO (2017)
Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma
Christopher Fung et al.
CANCER LETTERS (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
Meng Wang et al.
CANCER RESEARCH (2014)
Cancer stem cells and radioresistance
Kiera Rycaj et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis
Shen Keren et al.
TUMOR BIOLOGY (2014)
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Mark A. Lemmon et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor
Nicholas J. Bessman et al.
CELL REPORTS (2014)
A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer
Yinsheng Wang et al.
INTERNATIONAL JOURNAL OF GENOMICS (2014)
EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression
Katrijn Van Assche et al.
FRONTIERS IN ONCOLOGY (2014)
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma
Lei Ma et al.
FEBS JOURNAL (2013)
Prognostic Role of Epidermal Growth Factor Receptor in Head and Neck Cancer: A Meta-Analysis
Xiaoli Zhu et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
S. Yoshikawa et al.
ONCOGENE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Extracellular Domain Mutations in EGFR Occur Uniquely in Glioblastoma and Favor Ligand-independent Formation of the Active State
S. L. McGovern et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
Barbara Angulo et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
L. Licitra et al.
ANNALS OF ONCOLOGY (2011)
INTEGRATING EPIDERMAL GROWTH FACTOR RECEPTOR ASSAY WITH CLINICAL PARAMETERS IMPROVES RISK CLASSIFICATION FOR RELAPSE AND SURVIVAL IN HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Christine H. Chung et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
The molecular biology of head and neck cancer
C. Rene Leemans et al.
NATURE REVIEWS CANCER (2011)
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma
Maria Sundvall et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
MECHANISMS OF RESISTANCE TO EGFR INHIBITORS IN HEAD AND NECK CANCER
Jonathan B. Cooper et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2009)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients
Eva Bandres et al.
ORAL ONCOLOGY (2007)
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer
Stephane Temam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor biology in head and neck cancer
Shailaja Kalyankrishna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase
K Dittmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting
P Matar et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
